# PT-141 References: The Bremelanotide Citation Record

> PT-141 references: the full cited record behind this digest — the RECONNECT trials, the FDA label, the mechanism and neuroimaging studies, with PMIDs and DOIs.

Every claim on this site maps to one of these sources — peer-reviewed studies, reviews, and the FDA prescribing information, with PMIDs and DOIs.

## How to read this list

These are the sources cited across the site, numbered to match the inline markers. They include the founding melanocortin pharmacology, the two Phase 3 RECONNECT trials and their long-term extension, the human fMRI mechanism study, the FDA prescribing information, regulatory and review articles, and a forensic study on unregulated supply. Where a study is paywalled, the PubMed or DOI link still resolves to the abstract and metadata. PT-141 references here are the bremelanotide research record; nothing on this site relies on a claim absent from this list.

## References

[1] Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. https://pubmed.ncbi.nlm.nih.gov/12851303/
[2] Pfaus J, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101:10201-10204. https://pubmed.ncbi.nlm.nih.gov/15226502/
[3] Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599840/
[4] Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. https://pubmed.ncbi.nlm.nih.gov/31599847/
[5] Thurston L, Hunjan T, Mills EG, et al. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. J Clin Invest. 2022;132(19):e152341. https://pubmed.ncbi.nlm.nih.gov/36189794/
[6] Borland JM, Kohut-Jackson AL, Peyla AC, Hall MA, Mermelstein PG, Meisel RL. Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder. Neuropharmacology. 2025;267:110299. https://pubmed.ncbi.nlm.nih.gov/39793696/
[7] U.S. Food and Drug Administration / DailyMed. Bremelanotide Injection — US Prescribing Information. 2019. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9
[8] Hedlund P. PT-141 Palatin. Curr Opin Investig Drugs. 2004. https://pubmed.ncbi.nlm.nih.gov/15134289/
[9] Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel). 2020;13(3):40. https://doi.org/10.3390/ph13030040
[10] Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019;79:1599-1606. https://pubmed.ncbi.nlm.nih.gov/31312037/
[11] Croft HA. Understanding the Role of Serotonin in Female Hypoactive Sexual Desire Disorder and Treatment Options. J Sex Med. 2017. https://doi.org/10.1016/j.jsxm.2017.10.068
[12] Aughton KL, Hamilton-Smith K, Gupta J, Morton JS, Wayman CP, Jackson VM. Pharmacological profiling of neuropeptides on rabbit vaginal wall and vaginal artery smooth muscle in vitro. Br J Pharmacol. 2008. https://doi.org/10.1038/bjp.2008.253
[13] Mestria S, Odoardi S, Frison G, Strano Rossi S. LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs. Drug Test Anal. 2021. https://doi.org/10.1002/dta.2986

---

A spectrometer-style readout of the PT-141 (bremelanotide) record — every value logged to its source and marked in-spec or contested, the lone 2019 approval for premenopausal HSDD calibrated against every off-label and research-chemical use that sits outside its band; no clinic behind the instrument and nothing here prescribed, dosed, or sold.